1. Home
  2. Press release
Jul 22, 2020 17:04 JST

Source: Eisai

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

TOKYO, Jul 22, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.

Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally. The latest data on the analysis of occurrence of amyloid-related imaging abnormalities-edema (ARIA-E) and brain Aβ levels from the ongoing open-label extension study (OLE) portion of the Phase II study (Study 201) will also be presented.

The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.

Eisai is also planning to host a satellite symposium "Development of the A/T/N/x Classification System for Different Context of Use Across the Alzheimer's Disease Continuum: State-of-the-Art and future Perspectives for Clinical Practice and Therapy Development". Dr. Jeffrey Cummings (Chair), Dr. Clifford Jack, and Dr. Kaj Blennow, three renowned AD researchers and clinicians, will provide a comprehensive overview of the significance and conceptual framework of the A/T/N/x categorization system in the AD continuum. Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.

Regarding aducanumab, for which submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval as an Alzheimer's Disease treatment was completed in July 2020, Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States) will conduct an oral presentation of the previously publicized topline results of Phase III studies EMERGE and ENGAGE. This data has been shared at prior medical congresses.

BAN2401 and aducanumab are being jointly developed by Eisai and Biogen Inc.

Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
 
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
 
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
 
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
 
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
 
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31 2025 08:30 JST
 
More Press release >>

Latest Press Release


The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST

GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST

Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems

Sep 12, 2025 14:19 JST

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST

TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST

CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sep 11, 2025 20:37 JST

Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development

Sep 11, 2025 18:35 JST

GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sep 11, 2025 17:24 JST

GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sep 11, 2025 16:46 JST

JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban"
Sep 11, 2025 13:00 JST

Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sep 11, 2025 10:35 JST

TGR Plans to Reproduce Engine Parts for Corolla Levin / Sprinter Trueno (AE86)
Sep 10, 2025 18:11 JST

TANAKA Acts as Category Sponsor for the LIGA.i Blind Soccer Top League 2025
Sep 10, 2025 03:00 JST

Toyota Submits Fourth Progress Report on Measures to Prevent Recurrence
Sep 09, 2025 19:26 JST

The 46th Honda Prize 2025 Awarded to Dr. Kenichi IGA
Sep 09, 2025 19:06 JST

Lexus world premieres the new IS
Sep 09, 2025 18:26 JST

Toni Bou Wins 19th Consecutive FIM Trial World Championship Title
Sep 08, 2025 18:53 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sep 08, 2025 17:49 JST

Honda to Commercialize UNI-ONE Hands-Free Personal Mobility Device
Sep 08, 2025 15:56 JST

Mitsubishi Power Signs Contract to Supply Two M701JAC Gas Turbines to O Mon 4 Power Plant
Sep 08, 2025 15:36 JST
 More Latest Release >>